| DVC Deutsche Venture Capital As one of the leading venture capitalists with offices in Munich and Berlin, DVC has expanded its position in the European market continuously. Since its formation in 1998, DVC selectively invests in innovative, technology oriented companies in the markets of information and communication technology, microsystems and life science. We invest in all stages of development from seed financing, new establishment of companies and growth financing to public offerings, we support the formation of highly motivated high-tech companies. In doing so, we build on promising technologies, profit oriented business models, a clearly defined customer benefit and a quality management team. Each sector has its experienced team of investment managers, consisting of operational, technical and financial experts. Due to our experience and our good contacts in the VC business, we support you in turning your technological leadership into an international market success. |
 |
| Global
Life Science Ventures Global Life Science Ventures is an independent venture capital fund dedicated to the life sciences. With offices in Germany, Switzerland and the UK, GLSV focuses on investments in early to late stages throughout Europe, the U.S., and Israel. Its predecessor fund, Global Life Science, advised by Life Science Ventures, was founded in 1996 with €66 million and still holds 13 investments following three exits through IPO/ M&A. In 2002, GLSV II raised another €143 million. Its team of seasoned professionals continues the proven investment strategy and brings together a broad set of know-how and complementary experience from top pharma & biotech management, R&D, venture capital, consulting, and academia. GLSV is a pro-active syndicate player and has alliances with two venture capitalists from the US. Global Life Science Ventures GmbH Global Life Science Ventures AG Global Life Science Ventures Ltd. |
 |
| Kirchhoff Consult AG Kirchhoff Consult consists of a team of financial analysts, IR experts,issuing consultants, business journalists and communication designers. Our aim is to create a lively, convincing and sustained dialog between businesses and investors at each stage of a company's development. We advise start-ups during the entire capital procurement process. We organize and design corporate communication both in terms of content and visual aspects. All our staff members consider themselves to be dedicated consultants and partners of their clients at any particular time. We have both long-term mandates with significant corporations listed on the DAX and innovative, successful start-up companies. |
|
Morgan Lewis &
Bockius LLP Founded in 1873, Morgan, Lewis & Bockius LLP (“Morgan Lewis”) is one of the largest law firms in the US and has developed to a leading international firm with a total of over 1,100 fee-earners, based at 13 offices in the US, Europe and the Far East. The firm’s German practice group consists of lawyers located in Frankfurt, New York, Washington, Philadelphia and London, all of whom speak fluent German. Morgan Lewis’ Frankfurt Office: The Frankfurt office is staffed by German and American lawyers, primarily assisting corporate clients in cross-border transactions involving Germany, the United States and the EU. Its practice areas comprise Corporate Law (including M&A and, in particular, Takeover Law), Financial Services, Technology as well as European and German Antitrust Law. The firm also acts as outside general counsel on US law to European companies and their US subsidiaries. The clients of the Frankfurt office range from some of the largest multinationals to start-up companies. |
|
Novartis Pharma
AG Novartis (NYSE: NVS) is a world leader in healthcare with core businesses in pharmaceuticals, consumer health, generics, eye-care, and animal health. In 2001, the Group's businesses achieved sales of CHF 32.0 billion (USD 19.1 billion) and a net income of CHF 7.0 billion (USD 4.2 billion). The Group invested approximately CHF 4.2 billion (USD 2.5 billion) in R&D. Headquartered in Basel, Switzerland, Novartis employs about 72 600 people and operates in over 140 countries around the world. |
|
SWX Swiss Exchange The SWX Swiss Exchange is one of the world’s leading and most technologically advanced securities exchanges. In 1996, floor-based trading in Switzerland was supplanted by electronic trading. This fully automated trading, clearing and settlement system remains unique in the world. At the click of a mouse, an order is executed, cleared, paid for and confirmed. The SWX Swiss Exchange offers its customers first-rate securities exchange services and a broad range of investment products. The SWX Swiss Exchange provides innovative, international
companies with access to the Swiss capital market. A public offering
in one of its segments affords issuing companies a high degree of
global visibility among investors, especially those with a heightened
interest in certain sectors. An IPO in Switzerland represents an
attractive means of obtaining equity financing especially for companies
from the life science and IT sectors as well as the micro- and nanotechnology
industries. |
 |